INVESTORS NEWS CAREERS CONTACT GLOBAL NEED OUR SOLUTION PIPELINE ABOUT US Latest News The global vaccine market is growing steadily, and Vaxart is developing next-generation oral vaccines that could replace injectable vaccines, target new diseases, and have a major impact on the never-ending battle of the human race with infectious diseases all across the globe. Explore our latest news and publications. Latest Press Releases December 2021 Vaxart Announces Acquisition of Second GMP Manufacturing Facility November 2021 Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021 November 2021 Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart VIEW MORE Recent Publications Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, Gottlieb K, Trager G, Tucker SN. JCI Insight. 2018;Jul 12 Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule Kim L, Martinez CJ, Hodgson KA, Trager GR, Brandl JR, Sandefer EP, Doll WJ, Liebowitz D, Tucker SN. Sci Rep. 2016;Nov 24. Oral Modeling of an Adenovirus-Based Quadrivalent Influenza Vaccine in Ferrets and Mice Scallan CD, Lindbloom JD, Tucker SN. Infectious Diseases and Therapy. 2016;Apr 12. High Titre Neutralising Antibodies to Influenza after Oral Tablet Immunisation: A Phase 1, Randomised, Placebo-Controlled Trial Liebowitz D, Lindbloom JD, Brandl JR, Garg SJ, Tucker SN. Lancet Infectious Diseases. 2015 Sep;15(9):1041-8. VIEW MORE © 2021 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy